MedElevator
Войти в исследования Kidney international reports · 2026
Systematic Review of Kidney Involvement in Antisynthetase Syndrome.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Qi-Shun, Yang Ling, Lin Xin, Wu Zhang-Li, Yu Zhi-Liang, Zeng Ya-Yun
Аннотация
INTRODUCTION: Antisynthetase syndrome (ASyS) is a rare autoimmune disorder characterized by autoantibodies targeting aminoacyl-tRNA synthetases. Kidney involvement has been historically regarded as uncommon and remains poorly characterized.
METHODS: We conducted a systematic review using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines (PROSPERO: CRD420261282317). MEDLINE, Scopus, Web of Science, and Google Scholar were searched from inception to January 2026. We included adults with biopsy-proven or clinically defined kidney involvement in ASyS. Risk of bias was assessed using Joanna Briggs Institute tools; certainty of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation framework.
RESULTS: Thirty-eight articles comprising 52 patients were included. Kidney disease presented with or following interstitial lung disease (ILD) in 81% of cases. Among 35 biopsied patients, membranous nephropathy (29%), pauci-immune crescentic glomerulonephritis (23%), acute tubular necrosis (17%), and tubulointerstitial nephritis (11%) were identified. Non-Jo1 antibodies predominated in vasculitic phenotypes and were associated with higher peak creatinine than anti-Jo1 (4.7 vs. 2.3 mg/dl; P = 0.01). Corticosteroid monotherapy achieved complete recovery in 48% of mild disease, whereas rituximab was effective in 6 of 8 refractory cases. At a median of 18 months follow-up, 13% progressed to chronic kidney disease (CKD) stages 4 and 5.
CONCLUSION: Kidney involvement in ASyS carries substantial clinical significance. Non-Jo1 serotype may predict worse kidney outcomes, though this association requires confirmation in prospective cohorts with multivariable adjustment. Routine kidney surveillance and early antibody-guided immunosuppression may improve outcomes, pending validation.
METHODS: We conducted a systematic review using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines (PROSPERO: CRD420261282317). MEDLINE, Scopus, Web of Science, and Google Scholar were searched from inception to January 2026. We included adults with biopsy-proven or clinically defined kidney involvement in ASyS. Risk of bias was assessed using Joanna Briggs Institute tools; certainty of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation framework.
RESULTS: Thirty-eight articles comprising 52 patients were included. Kidney disease presented with or following interstitial lung disease (ILD) in 81% of cases. Among 35 biopsied patients, membranous nephropathy (29%), pauci-immune crescentic glomerulonephritis (23%), acute tubular necrosis (17%), and tubulointerstitial nephritis (11%) were identified. Non-Jo1 antibodies predominated in vasculitic phenotypes and were associated with higher peak creatinine than anti-Jo1 (4.7 vs. 2.3 mg/dl; P = 0.01). Corticosteroid monotherapy achieved complete recovery in 48% of mild disease, whereas rituximab was effective in 6 of 8 refractory cases. At a median of 18 months follow-up, 13% progressed to chronic kidney disease (CKD) stages 4 and 5.
CONCLUSION: Kidney involvement in ASyS carries substantial clinical significance. Non-Jo1 serotype may predict worse kidney outcomes, though this association requires confirmation in prospective cohorts with multivariable adjustment. Routine kidney surveillance and early antibody-guided immunosuppression may improve outcomes, pending validation.